A warning for the entire drug class
Rather than singling out semaglutide, the ingredient that has drawn the most attention, the FDA applied the requirement to the entire class of GLP-1 receptor agonists, noting that NAION cases have been reported in post-marketing surveillance for every GLP-1 drug currently on the market. The list includes:
- Semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro, Zepbound).
- Liraglutide (Victoza, Saxenda), dulaglutide (Trulicity) and exenatide.
- The combination products Xultophy and Soliqua, plus the oral drug orforglipron (Foundayo), approved in 2026.
The FDA acknowledged that no single data source settled the matter. According to Pharmacy Times, the clinical trial analysis included only 15 probable NAION events, animal data did not reveal a mechanism, and results from an FDA real-world study varied by comparator. Taken together, however, the agency concluded that patients and doctors should be informed.
NAION: a silent threat to sight
NAION occurs when blood flow to the front part of the optic nerve decreases, although its underlying cause is not fully understood. It usually affects one eye, with notable warning signs:

















